fda category 2 bulk drug substances bpc-157 compounding list just got voted in favor to be added to the 503A list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank The Food and Drug Administration's

Current treatments are largely palliative and do not address the underlying fibrosis

L.NangakuM.et al (2023)

The otic formulations or compositions described herein are solution formulations or compositions

Figure 1 4 Drug delivery for Alzheimer's disease: formulations, ideal properties, systemically relevant effects, and delivery strategies of nanoparticles 4.1 Ideal physicochemical properties of nanoparticles for Alzheimer's disease 4.1.1 Size and charge Basically, for the treatment of AD and other central nervous system (CNS) disorders, nanoparticles with diameters of ~200 nm are considered optimal for the systemic pathway, as larger nanoparticles are more likely to be cleared by the reticuloendothelial system (RES) (Markova et al., 2022)